Loading...
LGNYZ
OTCM
Market cap5.74bUSD
Nov 19, Last price  
0.05USD
1Q
-8.00%
Jan 2017
193.18%
Name

Ligand Pharmaceuticals Inc

Chart & performance

D1W1MN
OTCM:LGNYZ chart
P/E
0.01
P/S
0.00
EPS
6.22
Vol. 1Y
537.54%
Shs. 5Y
4.63%
Rev. 5Y
10.39%
Div Yld LY
1.67%
Div Yld TTM
7.20%
Revenues
268m
+60.40%
140,960,00012,894,00027,315,00038,940,00023,538,00030,037,00031,388,00048,974,00064,538,00071,914,000108,973,000141,102,000251,453,000120,282,000163,562,000241,544,000196,245,000131,314,000167,133,000268,087,000
Net income
124m
P
-31,743,000281,688,000-98,114,000-1,948,000-12,515,00010,176,000-527,00011,421,00012,024,000257,305,000-1,636,00012,556,000143,321,000629,302,000-2,985,00057,138,000-33,361,00052,154,000-4,032,000124,453,000
CFO
49m
-49.14%
-138,521,000-97,727,000-20,625,000-33,801,000-27,067,000-1,172,000161,00020,690,00020,566,00041,727,00063,001,00093,568,000194,059,000-29,336,00054,586,00078,798,000137,850,00049,577,00097,047,00049,359,000
Dividend
Jun 26, 20260.002541 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Ligand Pharmaceuticals Incorporated functions as a global biopharmaceutical entity, concentrating on the advancement and licensing of pharmaceutical assets. Its diverse portfolio includes commercial products targeting a wide array of serious health conditions. Key therapeutic offerings comprise Kyprolis and Evomela for the treatment of multiple myeloma, alongside Rylaze, an asparaginase formulation designed for both adult and pediatric patients battling acute lymphoblastic leukemia or lymphoblastic lymphoma. The company also provides Filspari, a dual endothelin and angiotensin II receptor antagonist, currently being developed for specific rare kidney diseases and as a non-immunosuppressive treatment for immunoglobulin A nephropathy. Further extending its reach, Ligand's portfolio features a teriparatide injection product for osteoporosis management. In the vaccine space, Vaxneuvance aims to prevent invasive disease caused by Streptococcus pneumoniae serotypes, while Pneumosil offers a pneumococcal conjugate vaccine primarily for children. A notable advancement is TZIELD, a CD3-directed antibody indicated to postpone the progression to Stage 3 type 1 diabetes in adults and children aged eight years and older who have Stage 2 T1D. Many of Ligand's solutions leverage its proprietary Captisol technology, enhancing drug formulations. Examples include Nexterone (a Captisol-enabled amiodarone), Zulresso (a Captisol-enabled brexanolone for postpartum depression), and Veklury, an antiviral treatment for moderate or severe COVID-19. The Captisol platform also supports Noxafil-IV, an IV formulation of posaconazole. Additional products in their repertoire address various indications such as post-menopausal symptoms (Duavee), autoimmune diseases (Exemptia), breast cancer (Vivitra), and other conditions through Bryxta and Zybev. Beyond its licensed therapies, Ligand also directly markets its Captisol materials. The company fosters strategic alliances, licenses, and business relationships with prominent pharmaceutical firms, including Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Ligand Pharmaceuticals Incorporated, founded in 1987, maintains its headquarters in Jupiter, Florida.

Key people

Independent Chairman of the Board · since 2017
Chief Executive Officer, Director · since 2022
Octavio Espinoza
Chief Financial Officer · since 2022
Andrew Reardon
Chief Legal Officer · since 2022
Independent Director · since 2006
Nancy Gray
Independent Director · since 2017
Jason Haas
Independent Director · since 2022
Independent Director · since 2011
Stephen Sabba
Independent Director · since 2008
Martine Zimmermann
Independent Director · since 2023
IPO date
Nov 18, 1992
Employees
76
Domiciled in
US
Incorporated in
US
Legal address
C/O CORPORATION SERVICE COMPANY
251 LITTLE FALLS DRIVE
WILMINGTON, DE 19808
US
Headquarters
555 Heritage Drive
Suite 200
Jupiter, FL 33458
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT